Intra-Cellular Therapies Inc (ITCI) EVP Michael Halstead Sells 21,458 Shares

Intra-Cellular Therapies Inc (NASDAQ:ITCI) EVP Michael Halstead sold 21,458 shares of Intra-Cellular Therapies stock in a transaction on Friday, January 4th. The stock was sold at an average price of $11.46, for a total transaction of $245,908.68. Following the sale, the executive vice president now owns 24,757 shares in the company, valued at $283,715.22. The sale was disclosed in a document filed with the SEC, which is available through this link.

Michael Halstead also recently made the following trade(s):

  • On Monday, January 7th, Michael Halstead sold 3,108 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $12.42, for a total transaction of $38,601.36.

Shares of Intra-Cellular Therapies stock opened at $13.14 on Friday. Intra-Cellular Therapies Inc has a 1 year low of $10.21 and a 1 year high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.09. Equities analysts expect that Intra-Cellular Therapies Inc will post -2.95 earnings per share for the current year.

Several research analysts have issued reports on the stock. Leerink Swann reissued an “outperform” rating on shares of Intra-Cellular Therapies in a research report on Friday, October 19th. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. Cantor Fitzgerald set a $32.00 price objective on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. Canaccord Genuity set a $31.00 price objective on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Wednesday, December 12th. Finally, BidaskClub raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Friday, September 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.75.

Institutional investors have recently modified their holdings of the business. Quantbot Technologies LP boosted its holdings in shares of Intra-Cellular Therapies by 5,520.7% in the third quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,527 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in shares of Intra-Cellular Therapies by 127.8% in the third quarter. Public Employees Retirement Association of Colorado now owns 5,687 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 3,190 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of Intra-Cellular Therapies in the second quarter valued at about $167,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Intra-Cellular Therapies by 53.0% in the second quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 3,339 shares in the last quarter. Finally, Tocqueville Asset Management L.P. boosted its holdings in shares of Intra-Cellular Therapies by 42.7% in the second quarter. Tocqueville Asset Management L.P. now owns 25,060 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 7,500 shares in the last quarter. 69.53% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.wkrb13.com/2019/01/11/intra-cellular-therapies-inc-itci-evp-michael-halstead-sells-21458-shares.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Featured Story: How are institutional investors different from individual investors?

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply